Chitosan-based self-assembled nanocarriers coordinated to cisplatin for cancer treatment.
Ronny TrummerWorranan RangsimawongWarayuth SajomsangMont Kumpugdee-VollrathPraneet OpanasopitPrasopchai PatrojanasophonPublished in: RSC advances (2018)
Polymeric nanocarriers were prepared via a dialysis method using three chitosan derivatives, N -benzyl- N , O -succinyl chitosan (BSCT), N -naphthyl- N , O -succinyl chitosan (NSCT), and N -octyl- N-O -succinyl chitosan (OSCT) and were coordinated to cisplatin. The nanocarrier properties and cytotoxicity on the human carcinoma cells, HN22 (head and neck), were investigated. In addition, intracellular cisplatin accumulation, apoptosis induction and toxicity on renal cells were also evaluated. The findings revealed that the succinyl groups of the polymers were perfectly deprotonated and bound with cisplatin by co-ordinate bonds at pH 8.5. Among the derivatives, BSCT exhibited the highest cisplatin loading and release in simulated physiological medium. The cytotoxicities on HN22 cells of cisplatin-loaded BSCT nanocarriers were lower than that of free cisplatin, however, they presented a greater percentage of early apoptosis in HN22 cells and could decrease cisplatin induced renal cell death. In conclusion, the BSCT self-assembly nanocarrier might be a cisplatin carrier for sustained release, which provides prolonged antitumour treatment and reduced nephrotoxicity.